Eye Associates, Sydney, New South Wales, Australia; Glaucoma Unit, Sydney Eye Hospital, Sydney, New South Wales, Australia; Department of Ophthalmology, University of Sydney, New South Wales, Australia
The early reports on intraocular bevacizumab injections talked about a transient predictable probably volume-related rise in intraocular pressure (IOP). As the usage of the drug increased across the globe, sustained IOP elevation was noted. This article provides an insightly into the causes of IOP spikes and its impact on glaucoma practice.
